



CONTAINS CONFIDENTIAL PATIENT INFORMATION

Crisaborole (Eucrisa)

Prior Authorization of Benefits (PAB) Form

Complete form in its entirety and fax to:

Prior Authorization of Benefits Center at 1-844-512-9004

Provider Help Desk 1-800-454-3730

1. Patient information

2. Physician information

Patient name: _____	Prescribing physician: _____
Patient ID #: _____	Physician address: _____
Patient DOB: _____	Physician phone #: _____
Date of Rx: _____	Physician fax #: _____
Patient phone #: _____	Physician specialty: _____
Patient email address: _____	Physician DEA: _____
	Physician NPI #: _____
	Physician email address: _____

3. Medication

4. Strength

5. Directions

6. Quantity per 30 days

_____	_____	_____	Specify: _____
-------	-------	-------	----------------

7. Diagnosis: _____

8. Approval criteria: CHECK ALL BOXES THAT APPLY

Note: Any areas not filled out are considered not applicable to your patient and MAY AFFECT THE OUTCOME of this request.

Prior authorization is required for Eucrisa (crisaborole). Payment will be considered for patients when the following criteria are met: 1) Patient has a diagnosis of mild to moderate atopic dermatitis; and 2) Patient is within the FDA labeled age; and 3) Patient has failed to respond to good skin care and regular use of emollients; and 4) Patient has documentation of an adequate trial and therapy failure with two preferred medium to high potency topical corticosteroids for a minimum of 2 consecutive weeks; and 5) Patient has documentation of a previous trial and therapy failure with a topical immunomodulator for a minimum of 4 weeks; and 6) Patient will continue with skin care regimen and regular use of emollients. 7) Quantities will be limited to 60 grams for use on the face, neck, and groin and 100 grams for all other areas, per 30 days. The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Has patient failed to respond to good skin care and regular use of emollients? Yes No

Document emollient use: Product name, dosing instructions & duration of use: _____

Will patient continue with skin care regimen and regular use of emollients?

Yes Emollient to be used: _____ No

Preferred Medium to High Potency Corticosteroid Trial 1:
 Drug name & dose: _____ Trial dates: _____

Failure reason: _____

<https://providers.amerigroup.com/IA>



CONTAINS CONFIDENTIAL PATIENT INFORMATION
Crisaborole (Eucrisa)
Prior Authorization of Benefits (PAB) Form
 Complete form in its entirety and fax to:
Prior Authorization of Benefits Center at 1-844-512-9004

Patient name: _____ **Patient ID #:** _____

Preferred Medium to High Potency Corticosteroid Trial 2:
 Drug name & dose: _____ Trial dates: _____
 Failure reason: _____

Preferred Topical Immunomodulator Trial:
 Drug name & dose: _____ Trial dates: _____
 Failure reason: _____

Affected area to be treated: _____

Medical or contraindication reason to override trial requirements: _____

Attach lab results and other documentation as necessary.

Patient name: _____ **Patient ID #:** _____

9. Physician signature

_____	_____
Prescriber or authorized signature	Date
<i>Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations, and exclusions. The submitting provider certifies that the information provided is true, accurate, and complete and the requested services are medically indicated and necessary to the health of the patient.</i>	
Note: Payment is subject to member eligibility. Authorization does not guarantee payment.	
The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation.	
If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.	